Standard BioTools (LAB) Announces Preliminary Fourth Quarter and Full Year 2023 Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street dips as higher yields, rising oil prices mark shaky start to SeptemberÂ
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue
January 8, 2024 8:30 AM ESTSOUTH SAN FRANCISCO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB) (Standard BioTools or the Company), driven by a bold purpose  Unleashing tools to accelerate breakthroughs in human health, today announced Standard BioTools and SomaLogic, Inc. preliminary and unaudited revenue results for the fourth quarter and full year 2023.
Standard BioTools expects fourth quarter 2023 revenue of approximately $28 million and full year 2023 revenue of approximately $106 million. The Companys preliminary full year 2023 revenue results represent growth of over 10% in core revenue1 driven by over 40% growth in instrument revenue, in each case as compared with... More
